The Journal of Experimental Medicine
PBL InterferonSource
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 2 September 2002. doi:10.1084/jem.20020267
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santoso, S.
Right arrow Articles by Chavakis, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santoso, S.
Right arrow Articles by Chavakis, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2002/9/679/ $5.00
The Journal of Experimental Medicine, Volume 196, Number 5, September 2, 2002 679-691

The Junctional Adhesion Molecule 3 (JAM-3) on Human Platelets is a Counterreceptor for the Leukocyte Integrin Mac-1

Sentot Santoso1, Ulrich J.H. Sachs1, Hartmut Kroll1, Monica Linder2, Andreas Ruf4, Klaus T. Preissner2 and Triantafyllos Chavakis2,3

1 Institute for Clinical Immunology and Transfusion Medicine, Internal Medicine, Justus-Liebig-University, D-35385 Giessen, Germany
2 Institute for Biochemistry, Internal Medicine, Justus-Liebig-University, D-35385 Giessen, Germany
3 3rd Department, Internal Medicine, Justus-Liebig-University, D-35385 Giessen, Germany
4 Institute for Clinical Laboratory Diagnostics, Klinikum Karlsruhe, 76133 Karlsruhe, Germany

Address correspondence to Sentot Santoso, Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University Giessen, Langhansstrasse 7, D-35385 Giessen, Germany. Phone: 49-641-99-41518; Fax: 49-641-99-41529. E-mail: sentot.santoso{at}immunologie.med.uni-giessen.de

The recently described junctional adhesion molecules (JAMs) in man and mice are involved in homotypic and heterotypic intercellular interactions. Here, a third member of this family, human JAM-3, was identified and described as a novel counterreceptor on platelets for the leukocyte ß2-integrin Mac-1 ({alpha}Mß2, CD11b/CD18). With the help of two monoclonal antibodies, Gi11 and Gi13, against a 43-kD surface glycoprotein on human platelets, a full-length cDNA encoding JAM-3 was identified. JAM-3 is a type I transmembrane glycoprotein containing two Ig-like domains. Although JAM-3 did not undergo homophilic interactions, myelo-monocytic cells adhered to immobilized JAM-3 or to JAM-3–transfected cells. This heterophilic interaction was specifically attributed to a direct interaction of JAM-3 with the ß2-integrin Mac-1 and to a lower extent with p150.95 ({alpha}Xß2, CD11c/CD18) but not with LFA-1 ({alpha}Lß2, CD11a/CD18) or with ß1-integrins. These results were corroborated by analysis of K562 erythroleukemic cells transfected with different heterodimeric ß2-integrins and by using purified proteins. Moreover, purified JAM-3 or antibodies against JAM-3 blocked the platelet-neutrophil interaction, indicating that platelet JAM-3 serves as a counterreceptor for Mac-1 mediating leukocyte–platelet interactions. JAM-3 thereby provides a novel molecular target for antagonizing interactions between vascular cells that promote inflammatory vascular pathologies such as in atherothrombosis.

Key Words: monoclonal antibody • adhesion molecule • integrins • neutrophils • athero- thrombosis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS